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Background: Long-term exercise interventions have been shown to improve vital capacity in cystic ﬁbrosis (CF). Yet, no data are available
indicating positive effects of long-term exercise training on FEV1.
Methods: 39 Swiss patients with CF were randomly divided into strength training (ST, n = 12), endurance training (AT, n = 17) and controls
(CONCH, n = 10), and also compared with age-matched Swiss (n = 35) and German (n = 701) CF registry data. A partially supervised training
of 3 × 30 min/week for 6 months took place with measurements at baseline and after 3, 6, 12 and 24 months. Primary outcome was FEV1 at
6 months.
Results: FEV1 increased signiﬁcantly in both training groups compared with CONCH (AT:+5.8 ± 0.95, ST:+7.4 ± 2.5, CONCH:−11.5 ± 2.7%
predicted, p b 0.001) and both registry groups at 6 months. At 24 months, changes in favour of the training groups persisted marginally compared
with CONCH, but not compared with registry data.
Conclusions: A partially supervised training over 6 months improved FEV1 but effects were basically gone 18 months off training. Regular long-
term training should be promoted as essential part of treatment in CF.
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programmes in children and adults with cystic fibrosis (CF)
[2–7]. In these studies, an increase in physical activity was
associated with a gain in exercise capacity [2–4,6] a stabilisation
or even an improvement in lung function [2,3,5] and a higher
quality of life [2,3,6]. Well-designed long-term physical condi-
tioning studies found an increase in forced vital capacity (FVC),
but not in FEV1 [2,3,5].
The primary objective of this randomised controlled trial
was to determine the effects of a 6-month partially supervised
aerobic training or a supervised strength training programme in
comparison to no intervention on FEV1 in patients with CF.
Secondary outcome measures included additional lung function
measures, markers of exercise capacity, physical activity, body
composition, and quality of life (QoL). We also tested long-
term effects 6 and 18 months after the end of the intervention.
2. Methods
2.1. Design and study population
Suitable patients were recruited from Swiss CF centres.
Inclusion criteria for this study were a diagnosis of CF, an age
of at least 12 years, a FEV1 of at least 35% of predicted [8], and
the ability to perform physical activity without harm. Exclusion
criteria were non-CF related chronic diseases and conditions
posing an increased risk to the patient when exercising. Forty-
two from 60 eligible patients agreed to participate. At the end of
the baseline assessments, patients were randomly assigned to
the strength training (ST), aerobic training (AT) or the control
group (CONCH) by a lot that was drawn by the subjects with
closed eyes from an opaque bag. Due to an unusual deteri-
oration of physical health in the CONCH, we added a separate
control group from a parallel study in Germany (COND) who
was tested with the same methodology and at the same time
points while the intervention arm was different from the Swiss
study [3]. We also retrieved lung function data from the Swiss
and German CF patients' registry with the same age than our
study population [9,10]. Written informed consent was ob-
tained from the patients and their guardians, if the patients were
under 18 years of age. The ethics committees of the medical
faculties of all participating centres approved the study protocol
and procedures.
2.2. Intervention
Patients in the intervention groups consented to perform
three training sessions per week of 30 to 45 minute duration for
the first six months of the study. Strength training was per-
formed in fitness centres which agreed to provide free access to
the participants for one year. Detailed information can be found
in the appendix. Briefly, the ST was monitored by diary cards
that had to be filled out at the fitness centres. The cards
contained the upper and lower body strength training exercises
including load and number of repetitions for the one predefined
set of 6–9 repetitions. A fitness instructor checked the cards
and provided assistance at least once each week over the studyperiod. This included the supervision of adequately conducting
the exercises and advice for adaptation of the load which was
increased by 5% if repetitions could be performed more than
9 times in one set. AT was based on individual preferences
performed either in a fitness centre or at home on a stationary
bike. Patients could have free access to a fitness centre or a bike
at home for one year that was provided free of charge. AT was
done initially at 65% of VO2peak which was controlled by heart
rate monitors that provided a target heart rate at the selected
oxygen uptake level. After each month the resistance of the
bike was increased by 10% if patients were able to continue to
pedal with ease after 30 min at the given resistance. Patients of
the intervention groups were called once a month during the
first 6 months of the study to check on their training adherence
and, if necessary, training visits were performed in case of open
questions or adherence problems. After the first six months,
patients in the intervention groups were encouraged to maintain
their training, but no further steps were taken to increase
adherence. Patients in the control group were told to keep their
physical activity level constant for the first 12 months of the
study. Free access to a fitness centre for one year after the first
year was offered to them. However, this option was not chosen
by any of the control subjects. No counselling or provision of
any suggestion regarding physical activity or exercise was given
to any of the participants during the second year of the study.
2.3. Outcome measures
Patients were seen in their respective centre at study entry
(December 2000 toMarch 2001) and after 3, 6, 12 and 24 months.
The intervention period lasted 6 months. All assessors were
trained in a pilot study twomonths before themain study. On each
visit, the primary outcome variable FEV1 was determined as well
as secondary outcome variables (additional pulmonary function
measures, anthropometry including body composition, short-
term muscle power, maximal aerobic power, physical activity).
Outcome assessors were blinded for pulmonary function, but
not for secondary outcomes with respect to the participant's
group allocation. However, they were not involved in the
supervision and delivery of the intervention. The order of the
testing was always the same: 1. anthropometry, 2. pulmonary
function, 3. Wingate test, 4. incremental cycle test after a rest
period of 30 min after the Wingate test. An additional predefined
secondary outcome (quality of life) will be reported separately.
Detailed information about testing procedures is provided
in the supplementary appendix. Skinfold thickness was deter-
mined at four sites and percent body fat and lean body mass
calculated [11,12]. FVC, FEV1 and residual volume relative to
total lung capacity (RV/TLC) were determined by standard
spirometry and for FVC and FEV1 expressed as %predicted [8].
Muscle power was assessed on a calibrated mechanically braked
cycle ergometer using the Wingate test protocol [13]. Subjects
then completed a continuous incremental cycling task to voli-
tional fatigue [14]. VO2peak was determined as highest VO2 over
30 s, and maximal Watt performance (Wmax) was taken as
the power maintained over the final completed 1-minute stage
during the test. Physical activity was determined by accelerometry
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group by cards that were meant to be regularly filled out during
each training session. AT mounted a heart rate monitor while they
were performing each exercise bout. Cards were checked and
heart rate monitors downloaded once a month.
2.4. Data analysis and statistics
Statistical analyses were based on an intention to treat
principle. The intervention and control groups were compared
for baseline characteristics using regression analyses adjusted for
age and gender. Additional adjustments for skinfold thickness and
muscle mass were done for aerobic performance. We used mixed
linear models with follow up values (at 3, 6, 12 and 24 months) as
dependent variables, group (ST, AT, CONCH, COND REGCH,
REGD), gender and age as fixed factors and the respective
baseline values as covariates. The German control group (COND)
and the two groups from the Swiss and German CF patient
registries were added due to the overall small sample size of the
study and due to an unusual deterioration of the Swiss control
group. For each outcome measure, the size of the intervention
effect is reported as difference between baseline and the follow up
value between the respective control or registry group (CH or D)
and each intervention group after adjusting for age, sex, and
baseline value. Secondary analyses were performed by testing
interactions of the intervention with gender and age. Aerobic and
anaerobic performance outcomes were additionally adjusted for
skinfold thickness and fat-free mass. All analyses were performed
using Stata statistical software release 10 (Statistical Solutions
Ltd., Cork, Ireland). Data are reported as means ± standard
deviation in tables and means ± 95% confidence intervals in
figures if not stated otherwise. Statistical significance was defined
at p b 0.05.
Our study was designed to have 3 arms of equal size (i.e., ST,
AT and control). The power calculation was targeted to a one way
ANOVA comparing average effects across arms at the usual
significance level of 5%. With 20 subjects per arm, we had more
than 80% power to detect a true overall difference in the mean
effects of the 3 treatments provided that the standard deviation of
these effects equalled at least 0.43 times the standard deviation
(SD) of the outcome within groups. For instance, this condition
would be satisfied if, compared with the control group, the true
average effects of the two treatments were both higher by 0.8 SD
or if the two treatment effects were higher by 0.9 SD and 0.45 SD,
respectively.
3. Results
Forty two patients entered the study. Despite extensive efforts,
it was not possible to recruit the intended 60 patients. Fig. 1 gives
sample size information throughout the study. Three patients
were excluded from the study at the baseline visit due to an initial
FEV1 below 35% predicted. No patient had to be excluded for the
other specified exclusion criteria. Three participants (2 AT, 1 ST)
dropped out of the study during the first 2 months due to
exacerbation (n = 1) or non-compliance (n = 2). Two patients of
the AT group died during the second year of the study (one in acar accident, one because of a deterioration of disease). An
additional three patients (1 AT, 2 CON) dropped out after the
6 month period for unclear reasons. Individual missing data
during the scheduled visits were due to malfunctioning of the
metabolic card (n = 3), a broken arm that prevented Wingate
testing (n = 1), or non-compliance with physical activity monitors
(n = 9).
Table 1 describes baseline characteristics of the study popu-
lation by group. There were no major differences among both
intervention and the respective control groups regarding clinical
characteristics and treatment regimens except for Wmax that was
significantly higher in the ST and time in VPA that was sig-
nificantly lower in the AT compared to COND.
Overall, participants in the training groups fulfilled at least
65% of all training sessions (i.e. 2 of 3 per week) and 80% of
all performed the requested 3 sessions per week. One-third of
patients did not report training in written form, but only orally
during testings. No adverse effects such as injuries, pneumotho-
rax, asthma attacks or hypoglycaemia occurred.
3.1. Primary and secondary outcome(s)
Results of all outcomes are documented in Figs. 2 and 3 (for
exact raw and adjusted values see Supplementary Tables 1–3).
As shown in Figs. 2 and 3, compared with CONCH FEV1 and
FVC were significantly improved in both training groups at 3, 6
and 12 months and remained improved at 24 months for ST.
When compared with COND and both registry groups (REGCH
and REGD), effects in favour of the intervention groups were
statistically highly significant at 6 months (all p b 0.001). Differ-
ences in changes ranged from 8 to 10% compared with pooled
baseline values, but all effects were lost 18 months off training.
Intervention effects compared to COND and the registry groups
were very comparable for FVC and FEV1 at each time point.
Compared with CONCH, hyperinflation expressed as RV/TLC
was significantly improved in both training groups at 6 months
and for ST even at 3 and 12 months. Compared with COND the
training effect on the reduction of hyperinflation was found for
the ST group at 6 months.
Compared with CONCH, effects on aerobic performance were
statistically significant at 6 months for both groups and at 3 and
12 months for the ST group. Compared with COND, changes of
VO2peak were statistically significant for the AT group.
All other secondary outcomes including body composition,
average or moderate-and-vigorous physical activity and muscle
power (Wingate test) were not significantly different among
groups at any assessment (Supplementary Table 1).
4. Discussion
This study documents that positive health effects of a 6-month
partially supervised exercise programme to improve pulmonary
function including FEV1, FVC and hyperinflation as well as
aerobic performance can be attained. These results are of major
importance as lung function and aerobic performance are relevant
determinants and predictors of health in CF [17–19]. Moreover,
no side effects of the training occurred which proves that exercise
Assessed for eligibility and
 invited to participate (n=42)
0 3 6 12 24 0 3 6 12 24 0 3 6 12 24 0 3 6 12 24
Primary outcome
FEV1 17 14 15 15 12 12 11 11 11 11 10 10 10 8 8 15 13 15 12 11
Secondary outcomes
FVC 17 14 15 15 12 12 11 11 11 11 10 10 10 8 8 15 13 13 12 11
RV/TLC 17 14 13 15 12 12 11 10 11 11 10 10 10 8 8 14 13 14 11 10
VO2peak 17 15 15 14 11 9 11 8 8 8 10 10 10 8 7 15 13 13 12 9
Wmax 17 15 15 15 11 12 11 11 11 11 10 10 10 8 7 15 13 13 11 10
physical activity 16 13 14 14 12 11 10 11 10 8 10 9 9 8 7 13 8 8 5 6
Mean power legs 15 12 13 12 9 12 12 11 11 11 10 10 10 8 8 14 11 14 12 11
Mean power arms 15 12 11 12 10 12 11 11 11 11 10 10 10 8 7
lean body mass 17 15 15 15 12 12 11 11 11 11 10 10 10 8 8 15 15 15 12 11
% bodyfat 17 15 15 15 12 12 11 11 11 11 10 10 10 8 8 15 15 12 11
FEV1 <35%pred (n=3)
Consented and present 
baseline measures 
(n=39)
for comparison due to an 
unexpected deterioration 
of lung function in the 
Controls CH Randomization
Aerobic Training 
(n=17)
Strength Training 
(n=12)
Controls CH         
(n=10)
Controls D             
(n=15)
month of assessment month of assessment month of assessment month of assessment
Fig. 1. Flow of participants. Flow of individual participants through study, with outcome measures.
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significant positive effects of the training were attained at the
end of the partially supervised training period at 6 months, but
at most subtle effects remained 6- and 18 months after the
programme was ended.
The finding of improved pulmonary function in both training
groups is without doubt clinically relevant. While short-term
improvement of FEV1 during a training period of 2 weeks in
hospital has been shown [6], this is the first long-term training
study in CF that documents significant training effects in favour
of FEV1. Other exercise trials documented improvements of FVC
with durations of training ranging from 6 months to 3 years
[2,3,5], but none of them reached significant improvements in
FEV1. The type of supervision with at least one weekly contact to
keep compliance and motivation up was sufficient. This finding
is supported by the loss of beneficial training effects, once thesupervision was stopped, and also by the fact that none of the
controls chose to take up the offered option of free access to a
fitness centre after the first year.
Why regular exercise might be effective in decreasing the loss
of pulmonary function is not well understood. Postulated
mechanisms are mechanical vibrations of the body, increased
ventilation facilitating mechanical cleaning of the airways [21],
and inhibition of the amiloride-sensitive sodium channel in
respiratory epithelium [22] leading to an increased water content
of the mucus in the CF lung during exercise and facilitating
mucus expectoration. Alternatively or additionally, exercise has
also been shown to stimulate anabolic mediators such as growth
hormone and insulin-like growth factor I in CF [23], andmay also
act through improvements in insulin resistance, immune function
[24], induction of tissue growth factors or through altered
neuroendocrine control of metabolism as suggested [25]. In the
Table 1
Baseline characteristics of participants.
Aerobic training Strength training Controls CH Controls D
Sample size, n 17 12 10 15
Females, n (%) 4 (25) 5 (42) 5 (50) 9 (60)
Age, yrs 23.8 [21.5–26.5] 19.0 [16.0–22.0] 20.3 [17.0–23.6] 19.5 [16.8–22.2]
Mutation ΔF508 homo-/heterocygot 8/4 8/3 3/4 7/4
Mutation 3995ins 0 1 3 0
Insulin treatment 3 2 0 0
IV antibiotics at least once a year 11 6 5 11
Exocrine pancreas insufficiency 16 12 9 14
Pseudomonas positive 16 10 10 9
Oral corticosteroids 1 1 0 1
BMI, kg/m2 19.1 [17.8–20.3] 19.4 [18.0–20.8] 19.6 [18.1–21.1] 20.9 [19.6–22.1]
Body fat, % 14.4 [12.5–16.4] 14.0 [11.7–16.2] 13.9 [11.5–16.4] 16.7 [14.7–18.7]
FFM, kg 46.0 [42.5–49.5] 47.5 [43.5–51.5] 47.9 [43.6–52.3] 49.2 [45.7–52.8]
FVC, % predicted 79 [71–87] 80 [71–90] 87 [77–97] 84 [75–92]
FEV1, % predicted 65 [55–74] 67 [57–78] 75 [63–87] 69 [59–79]
RV/TLC, % 37 [33–42] 37 [32–42] 33 [28–38] 40 [35–45]
Physical activity, cpm 376 [217–535] 438 [254–622] 397 [208–585] 465 [286–644]
Time in VPA, h/week 3.6 [2.3–4.9]b 5.1 [3.7–6.6] 3.8 [2.3–5.3] 6.2 [4.8–7.7]
VO2,peak mL/kg/min 35.0 [32.0–38.0] 37.7 [33.6–41.7] 39.1 [35.4–42.9] 38.0 [36.7–43.3]
Wmax, W/kg 3.2 [2.9–3.4] 3.6 [3.4–3.9]
bb 3.4 [3.1–3.7] 2.9 [2.7–3.2]
MP leg, W/kg 5.9 [5.4–6.5] 7.0 [6.4–7.5] 6.3 [5.7–6.9] 6.6 [6.0–7.1]
MP arm, W/kg 2.9 [2.5–3.2] 3.2 [2.9–3.6] 3.0 [2.6–3.4]
Values are adjusted means [95% CI] unless stated otherwise. Adjustments were done for sex, skinfolds and fat free mass (FFM).
CH: Swiss; D: German; BMI: body mass index; FFM: fat free mass; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; RV: residual volume; TLC:
total lung capacity; cpm: counts per minute; VPA: vigorous physical activity in hours per week; VO2peak: peak oxygen uptake; Wmax: maximal power over the final
completed 1-min stage; MP: mean power, W: Watts.
Sig differences to CONCH (a) and to COND (b); one symbol denotes p b 0.05, two symbols p b 0.001.
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reduction of hyperinflation as RV/TLC improved in parallel.
Although there is no literature of mechanisms that could help to
explain the positive effects of ST on lung function, it may be
related to the training of respiratory muscles and to an erecting of
the thorax that may have led to an opening of functional air space.
The difference in change of aerobic fitness (i.e.VO2peak and
Wmax) between the training and control groups at 6 months wasFig. 2. Changes in FEV1 in both training groups vs. controls. Change in forced
expiratory volume in 1 s (FEV1[%predicted], from baseline to 24 months in the
aerobic training group (AT), strength training group (ST), the Swiss (CONCH) and
German (COND) control groups. The primary outcome, i.e. the change in FEV1
after 6 months, is highlighted. Data are presented as means ± 95%CI. Adjust-
ments were done for age, sex and FEV1 baseline value. CONCH versus ST (
a) and
AT (b), COND versus ST(
c) and AT (d); one symbol denotes p b 0.05, two
symbols p b 0.01, three symbols p b 0.001.10–17% of baseline values. This positive effect was reached
right after the 6-month supervised intervention period, but faded
with time and was lost 18 months later. This is an important
finding, suggesting that training in order to be effective has
to be continuously supervised to reach long-term maintenance
of improved endurance performance. As only one [3] out of 6
randomised controlled exercise training studies [2–6] assessed
long-term effects after the training had stopped, the question
remains open whether type, intensity or duration of the training
regimen plays a role in determining long-term beneficial effects.
So far, a freely chosen and individualised physical activity
programme, even without supervision, seems to have the po-
tential for attaining persisting long-term effects up to at least
1.5 years after the end of training [3].
There were no differences in changes in percent body fat or
muscle mass among groups. This suggests that a significant
increase in muscle mass was not reached, not even in the ST
group where it may be expected after a 6 month training period. It
is possible that the intervention was too mild, the compliance of
the training intensity lower than reported, or that nutritional
requirements to increase muscle mass were not met. Alternative-
ly, peripheral muscles of patients may be unable to hypertrophy
due to progressive chronic disease or due to an inherited defect of
the muscle cell causing ineffective mitochondrial oxidative
phosphorylation as suggested [26].
There are some limitations of the study to be addressed. We
acknowledge that the Swiss control group was not representa-
tive of the general CF community although randomly selected.
The decline in lung function especially during the first year was
Fig. 3. Changes in lung function in both training groups vs. controls. Change in lung function (FVC [%predicted] and RV/TLC[%]) and aerobic performance
(VO2peak [ml∗kg−1∗min−1], Watts [W∗kg−1] from baseline to 24 months in the aerobic training group (AT) and strength training group (ST) compared with the
Swiss (CONCH) and German (COND) control groups. Data are presented as means ± 95%CI. All outcomes were adjusted for age, sex, the respective baseline value,
VO2peak and Watts additionally for skinfolds and fat free mass. CONCH versus ST (
a) and AT (b), COND versus ST(
c) and AT (d); one symbol denotes p b 0.05, two
symbols p b 0.01, three symbols p b 0.001.
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registries [9,10]. We therefore included a second control group
(COND) that was selected from a comparable study in Germany
which was highly representative when compared with the
German and Swiss CF registry (Fig. 4) and did not differ in
clinical characteristics and treatment regimens [9,10]. By com-
paring the training groups with the COND and also with both
age-matched registry groups, the effects of the intervention
became weaker, but were still statistically significant at 6 months
with a clinically meaningful improvement of FEV1 of about 10%.Fig. 4. Long-term changes of FEV1 in controls vs. CF registry data. Decline of
forced expiratory volume in 1 s (FEV1) in both CF control groups compared with
Swiss (REGCH, n = 35) and German (REGD, n = 701) cystic fibrosis registry data
(only patients with CF older than 12 years and with an FEV1 N 35% were
included, participants of the CONCH and COND were excluded). Data are
presented as means ± SE. Adjustments were done for age and sex.In contrast to the comparison with the Swiss CONCH no sig-
nificant long-term effects were observed on lung function which
was very consistent irrespective of comparison group. One reason
that might explain in part the more severe drop of physical health
in the CONCH is the occurrence of a frame shift mutation
3905insT of the CF gene that is associated with a severe
phenotype apparent in 3 of our 10 Swiss control subjects [27].
Despite major efforts to recruit 60 patients into the study, we
could only enrol 42. Nevertheless, power was sufficient to reveal
multiple significant and clinically meaningful results. Further-
more, we did not measure nutritional intakes which may have
helped to differentiate findings of the training on body com-
position. Although both control groups were comparable for most
outcomes including aerobic performance, vigorous physical
activity in the COND group was significantly higher, which
could have biassed our results. Due to a lack of compliance to
report each training session in about 35% of the study population,
a dose–response relation between training volume and change in
FEV1 could not be tested.
In conclusion, a 6-month supervised AT or ST programme led
to transient improvements in lung function including FEV1, and
an improvement in aerobic performance in patients with CF
underlining the importance of physical activity for all patients
regardless of their mutations. Further studies may reveal whether
a combination of aerobic and strength training may lead to more
beneficial changes in physical health. The absence of long-term
720 S. Kriemler et al. / Journal of Cystic Fibrosis 12 (2013) 714–720effects suggests that persisting changes of activity behaviour can
be attained only with continuation of an intervention that is at
least partially supervised which can easily be implemented in
every CF care.
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